NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

骨質疏鬆症治療藥的全球市場:各藥物類別、骨質疏鬆症類型、給藥途徑、性、流通管道、地區的競爭、預測、機會 (2026年)

Global Osteoporosis Drugs Market, By Drug Class, By Osteoporosis Disease Type, By Route of Administration, By Gender, By Distribution Channel, By Region, Forecast & Opportunities, 2026

出版商 TechSci Research 商品編碼 995911
出版日期 內容資訊 英文 112 Pages
商品交期: 請詢問到貨日
價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

骨質疏鬆症治療藥的全球市場:各藥物類別、骨質疏鬆症類型、給藥途徑、性、流通管道、地區的競爭、預測、機會 (2026年) Global Osteoporosis Drugs Market, By Drug Class, By Osteoporosis Disease Type, By Route of Administration, By Gender, By Distribution Channel, By Region, Forecast & Opportunities, 2026
出版日期: 2021年03月01日內容資訊: 英文 112 Pages
簡介

全球骨質疏鬆症治療藥的市場規模,從2020年的133億6000萬美元,預計到2026年超過201億7000萬美元,6.83%的年複合成長率。

停經後的女性的骨質疏鬆症的盛行率增加,及一般市民對骨質疏鬆症照護的認識高漲等,成為促進市場成長的主要原因。再加上先進新藥的開發為目的的研究開發活動的投資擴大,及臨床試驗以獲得核准的廣泛開發平台的存在等,預期提供骨質疏鬆症治療藥廠商有利的成長機會。

本報告提供全球骨質疏鬆症治療藥市場相關調查,各市場區隔為基礎的分析與預測,市場趨勢、競爭情形分析,及主要企業簡介等資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 COVID-19對全球骨質疏鬆症治療藥市場的影響

第4章 摘要整理

第5章 客戶的迴響

第6章 全球骨質疏鬆症治療藥市場預測

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各醫藥品分類(雙磷酸鹽,選擇的雌激素抑制劑調製器(SERM),副甲狀腺素療法,抑鈣素,RANKL抑制劑等)
    • 各給藥途徑(口服,注射,其他)
    • 各骨質疏鬆症類型(原發性骨質疏鬆症,續發性骨質疏鬆症)
    • 性別(女性,男性)
    • 各流通管道(醫院藥局,零售藥局,線上藥局)
    • 各企業
    • 各地區
  • 產品市場地圖

第7章 北美的骨質疏鬆症治療藥市場預測

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各醫藥品分類
    • 各給藥途徑
    • 各骨質疏鬆症類型
    • 性別
    • 各流通管道
    • 各國
  • 北美:各國分析
    • 美國
    • 墨西哥
    • 加拿大

第8章 歐洲的骨質疏鬆症治療藥市場預測

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各醫藥品分類
    • 各給藥途徑
    • 各骨質疏鬆症類型
    • 性別
    • 各流通管道
    • 各國
  • 歐洲:各國分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章 亞太地區的骨質疏鬆症治療藥市場預測

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各醫藥品分類
    • 各給藥途徑
    • 各骨質疏鬆症類型
    • 性別
    • 各流通管道
    • 各國
  • 亞太地區:各國分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 新加坡
    • 澳洲

第10章 南美的骨質疏鬆症治療藥市場預測

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各醫藥品分類
    • 各給藥途徑
    • 各骨質疏鬆症類型
    • 性別
    • 各流通管道
    • 各國
  • 南美:各國分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章 中東、非洲的骨質疏鬆症治療藥市場預測

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各醫藥品分類
    • 各給藥途徑
    • 各骨質疏鬆症類型
    • 性別
    • 各流通管道
    • 各國
  • 中東、非洲:各國分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第12章 市場動態

  • 促進因素
  • 課題

第13章 市場趨勢

第14章 競爭情形

  • 競爭預測
  • 企業簡介(主要企業)
    • F. Hoffmann-La Roche Ltd
    • Pfizer, Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Novartis International AG
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Amgen, Inc.
    • Allergan plc
    • Eli Lilly and Company
    • Radius Health, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Sanofi S.A.
    • Abiogen Pharma S.p.A
    • Merrion Pharmaceuticals Plc

第15章 策略性推薦事項

第16章 關於本公司&免責聲明

目錄
Product Code: 5081

Title:
Global Osteoporosis Drugs Market, By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), By Osteoporosis Disease Type (Primary Osteoporosis, Secondary Osteoporosis), By Route of Administration (Oral, Injectable, and Others), By Gender (Female, Male), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Forecast & Opportunities, 2026.

The global osteoporosis drugs market stood at USD13.36 billion in 2020 and is projected to grow at a CAGR of 6.83% to cross USD20.17 billion by 2026. The increase in the prevalence of osteoporosis in postmenopausal women and rising awareness among the public about osteoporosis care are some key factors propelling the market growth. Moreover, growing investment in R&D activities for the development of advanced new drug classes and a wide range of pipeline drugs for approval in clinical trials are expected to provide lucrative growth opportunities for osteoporosis drug manufacturers.

Osteoporosis drugs are used to treat osteoporosis, which is a bone disease. Osteoporosis may occur due to lower than normal peak bone mass and greater than normal bone mass loss. Other reasons behind this disease include a number of diseases or treatments such as anorexia, surgical removal of the ovaries, hyperthyroidism, alcoholism, and kidney disease. Moreover, lifestyle associated factors such as smoking and alcohol abuse can also promote osteoporosis. Hence these factors are leading to a spike in demand for osteoporosis drugs around the world.

The global osteoporosis drugs market can be segmented based on disease type, drug class, route of administration, gender, distribution channel and region. Based on the route of administration, the market can be segmented into oral, injectable, and others. Among them, the injectable segment is expected to witness high CAGR during the forecast period owing to the growing need for drugs that exhibit improved bioavailability rapid mode of action.

Regionally, North America dominated the global osteoporosis drugs market in 2020 owing to the rising prevalence of osteoporosis and easy availability of osteoporosis drugs in the region. However, Asia Pacific is expected to witness the fastest growth through 2026 owing to growing awareness about the benefits of osteoporosis drugs and thriving life science industry.

Major companies operating in the global osteoporosis drugs market include F. Hoffmann-La Roche Ltd, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Novartis International AG, GlaxoSmithKline Plc, Merck & Co. Inc., Amgen, Inc., Allergan plc, Eli Lilly and Company, Radius Health, Inc., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited, Sanofi S.A., Abiogen Pharma S.p.A., Merrion Pharmaceuticals Plc., among others. The market players are taking up growth strategies like collaborations, new product launches, partnership & acquisitions.

Years considered for this report:

Historical Years: 2016-2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022-2026

Objective of the Study:

  • To analyze the historical growth in the market size of the global osteoporosis drugs market from 2016 to 2019.
  • To estimate and forecast the market size of the global osteoporosis drugs market from 2021 to 2026 and growth rate until 2026.
  • To forecast global osteoporosis drugs market based on drug class, route of administration, company and regional distribution.
  • To identify drivers and challenges for global osteoporosis drugs market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global osteoporosis drugs market.
  • To identify and analyze the profile of leading players operating in the global osteoporosis drugs market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of osteoporosis drug manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global osteoporosis drugs market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • Osteoporosis drugs manufacturers, companies/partners and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to osteoporosis drugs
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as osteoporosis drug manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global osteoporosis drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Osteoporosis Drugs Market, By Osteoporosis Disease Type:

Primary Osteoporosis

Secondary Osteoporosis

  • Global Osteoporosis Drugs Market, By Drug Class:

Bisphosphonates

Selective Estrogen Inhibitors Modulator (SERM)

Parathyroid Hormone Therapy

Calcitonin

Rank Ligand Inhibitors

Others

  • Global Osteoporosis Drugs Market, By Route of Administration:

Oral

Injectable

Others

  • Global Osteoporosis Drugs Market, By Gender:

Male

Female

  • Global Osteoporosis Drugs Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

  • Global Osteoporosis Drugs Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Singapore

South America

  • Brazil
  • Argentina
  • Colombia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape:

Company Profiles: Detailed analysis of the major companies present in global osteoporosis drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information:

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Osteoporosis Drugs Market

4. Executive Summary

5. Voice of Customer

6. Global Osteoporosis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others)
    • 6.2.2. By Route of Administration (Oral, Injectable, and Others)
    • 6.2.3. By Osteoporosis Disease Type (Primary Osteoporosis, Secondary Osteoporosis)
    • 6.2.4. By Gender (Female, Male)
    • 6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.6. By Company (2020)
    • 6.2.7. By Region
  • 6.3. Product Market Map

7. North America Osteoporosis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Osteoporosis Disease Type
    • 7.2.4. By Gender
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Osteoporosis Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Osteoporosis Disease Type
        • 7.3.1.2.4. By Gender
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Mexico Osteoporosis Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Osteoporosis Disease Type
        • 7.3.2.2.4. By Gender
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. Canada Osteoporosis Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Osteoporosis Disease Type
        • 7.3.3.2.4. By Gender
        • 7.3.3.2.5. By Distribution Channel

8. Europe Osteoporosis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Osteoporosis Disease Type
    • 8.2.4. By Gender
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Osteoporosis Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Osteoporosis Disease Type
        • 8.3.1.2.4. By Gender
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. Germany Osteoporosis Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Osteoporosis Disease Type
        • 8.3.2.2.4. By Gender
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. United Kingdom Osteoporosis Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Osteoporosis Disease Type
        • 8.3.3.2.4. By Gender
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. Italy Osteoporosis Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Osteoporosis Disease Type
        • 8.3.4.2.4. By Gender
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Spain Osteoporosis Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Osteoporosis Disease Type
        • 8.3.5.2.4. By Gender
        • 8.3.5.2.5. By Distribution Channel

9. Asia-Pacific Osteoporosis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Osteoporosis Disease Type
    • 9.2.4. By Gender
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Osteoporosis Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Osteoporosis Disease Type
        • 9.3.1.2.4. By Gender
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. India Osteoporosis Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Osteoporosis Disease Type
        • 9.3.2.2.4. By Gender
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Japan Osteoporosis Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Osteoporosis Disease Type
        • 9.3.3.2.4. By Gender
        • 9.3.3.2.5. By Distribution Channel
    • 9.3.4. South Korea Osteoporosis Drugs Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Route of Administration
        • 9.3.4.2.3. By Osteoporosis Disease Type
        • 9.3.4.2.4. By Gender
        • 9.3.4.2.5. By Distribution Channel
    • 9.3.5. Singapore Osteoporosis Drugs Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Route of Administration
        • 9.3.5.2.3. By Osteoporosis Disease Type
        • 9.3.5.2.4. By Gender
        • 9.3.5.2.5. By Distribution Channel
    • 9.3.6. Australia Osteoporosis Drugs Market Outlook
      • 9.3.6.1. Market Size & Forecast
        • 9.3.6.1.1. By Value
      • 9.3.6.2. Market Share & Forecast
        • 9.3.6.2.1. By Drug Class
        • 9.3.6.2.2. By Route of Administration
        • 9.3.6.2.3. By Osteoporosis Disease Type
        • 9.3.6.2.4. By Gender
        • 9.3.6.2.5. By Distribution Channel

10. South America Osteoporosis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Osteoporosis Disease Type
    • 10.2.4. By Gender
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Osteoporosis Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Osteoporosis Disease Type
        • 10.3.1.2.4. By Gender
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Argentina Osteoporosis Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Osteoporosis Disease Type
        • 10.3.2.2.4. By Gender
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Colombia Osteoporosis Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Osteoporosis Disease Type
        • 10.3.3.2.4. By Gender
        • 10.3.3.2.5. By Distribution Channel

11. Middle East and Africa Osteoporosis Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Route of Administration
    • 11.2.3. By Osteoporosis Disease Type
    • 11.2.4. By Gender
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Osteoporosis Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Route of Administration
        • 11.3.1.2.3. By Osteoporosis Disease Type
        • 11.3.1.2.4. By Gender
        • 11.3.1.2.5. By Distribution Channel
    • 11.3.2. Saudi Arabia Osteoporosis Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Route of Administration
        • 11.3.2.2.3. By Osteoporosis Disease Type
        • 11.3.2.2.4. By Gender
        • 11.3.2.2.5. By Distribution Channel
    • 11.3.3. UAE Osteoporosis Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Route of Administration
        • 11.3.3.2.3. By Osteoporosis Disease Type
        • 11.3.3.2.4. By Gender
        • 11.3.3.2.5. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled (Leading Companies)
    • 14.2.1. F. Hoffmann-La Roche Ltd
    • 14.2.2. Pfizer, Inc.
    • 14.2.3. Teva Pharmaceuticals Industries Ltd.
    • 14.2.4. Novartis International AG
    • 14.2.5. GlaxoSmithKline Plc
    • 14.2.6. Merck & Co. Inc.
    • 14.2.7. Amgen, Inc.
    • 14.2.8. Allergan plc
    • 14.2.9. Eli Lilly and Company
    • 14.2.10. Radius Health, Inc.
    • 14.2.11. Sun Pharmaceutical Industries Ltd.
    • 14.2.12. Takeda Pharmaceutical Company Limited
    • 14.2.13. Sanofi S.A.
    • 14.2.14. Abiogen Pharma S.p.A
    • 14.2.15. Merrion Pharmaceuticals Plc

15. Strategic Recommendations

16. About Us & Disclaimer

(Note: The companies list can be customized based on the client requirements.)

List of Figures

  • Figure 1: Global Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 2: Global Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 3: Global Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 4: Global Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 5: Global Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 6: Global Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 7: Global Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 8: North America Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 9: North America Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 10: North America Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 11: North America Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 12: North America Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 13: North America Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 14: North America Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 15: United States Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 16: United States Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 17: United States Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 18: United States Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 19: United States Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 20: United States Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 21: United States Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 22: Mexico Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 23: Mexico Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 24: Mexico Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 25: Mexico Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 26: Mexico Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 27: Mexico Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 28: Mexico Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 29: Canada Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 30: Canada Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 31: Canada Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 32: Canada Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 33: Canada Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 34: Canada Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 35: Canada Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 36: Europe Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 37: Europe Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 38: Europe Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 39: Europe Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 40: Europe Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 41: Europe Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 42: Europe Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 43: France Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 44: France Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 45: France Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 46: France Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 47: France Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 48: France Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 49: France Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 50: Germany Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 51: Germany Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 52: Germany Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 53: Germany Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 54: Germany Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 55: Germany Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 56: Germany Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 57: United Kingdom Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 58: United Kingdom Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 59: United Kingdom Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 60: United Kingdom Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 61: United Kingdom Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 62: United Kingdom Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 63: United Kingdom Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 64: Italy Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 65: Italy Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 66: Italy Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 67: Italy Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 68: Italy Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 69: Italy Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 70: Italy Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 71: Spain Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 72: Spain Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 73: Spain Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 74: Spain Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 75: Spain Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 76: Spain Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 77: Spain Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 78: Asia-Pacific Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 79: Asia-Pacific Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 80: Asia-Pacific Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 81: Asia-Pacific Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 82: Asia-Pacific Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 83: Asia-Pacific Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 84: Asia-Pacific Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 85: China Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 86: China Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 87: China Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 88: China Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 89: China Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 90: China Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 91: China Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 92: India Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 93: India Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 94: India Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 95: India Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 96: India Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 97: India Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 98: India Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 99: Japan Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 100: Japan Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 101: Japan Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 102: Japan Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 103: Japan Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 104: Japan Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 105: Japan Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 106: South Korea Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 107: South Korea Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 108: South Korea Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 109: South Korea Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 110: South Korea Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 111: South Korea Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 112: South Korea Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 113: Singapore Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 114: Singapore Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 115: Singapore Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 116: Singapore Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 117: Singapore Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 118: Singapore Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 119: Singapore Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 120: Australia Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 121: Australia Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 122: Australia Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 123: Australia Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 124: Australia Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 125: Australia Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 126: Australia Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 127: South America Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 128: South America Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 129: South America Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 130: South America Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 131: South America Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 132: South America Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 133: South America Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 134: Brazil Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 135: Brazil Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 136: Brazil Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 137: Brazil Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 138: Brazil Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 139: Brazil Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 140: Brazil Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 141: Argentina Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 142: Argentina Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 143: Argentina Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 144: Argentina Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 145: Argentina Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 146: Argentina Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 147: Argentina Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 148: Colombia Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 149: Colombia Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 150: Colombia Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 151: Colombia Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 152: Colombia Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 153: Colombia Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 154: Colombia Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 155: Middle East and Africa Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 156: Middle East and Africa Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 157: Middle East and Africa Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 158: Middle East and Africa Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 159: Middle East and Africa Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 160: Middle East and Africa Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 161: Middle East and Africa Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 162: South Africa Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 163: South Africa Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 164: South Africa Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 165: South Africa Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 166: South Africa Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 167: South Africa Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 168: South Africa Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 169: South Arabia Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 170: South Arabia Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 171: South Arabia Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 172: South Arabia Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 173: South Arabia Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 174: South Arabia Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 175: South Arabia Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 176: UAE Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
  • Figure 177: UAE Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
  • Figure 178: UAE Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
  • Figure 179: UAE Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
  • Figure 180: UAE Osteoporosis Drugs Market Share, By Gender, 2016-2026F
  • Figure 181: UAE Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
  • Figure 182: UAE Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F